Animal models of β -hemoglobinopathies: utility and limitations

Bradley McColl
Jim Vadolas

Cell and Gene Therapy Laboratory,
Murdoch Childrens Research Institute,
Royal Children's Hospital, Parkville,
VIC, Australia

Abstract: The structural and functional conservation of hemoglobin throughout mammals has made the laboratory mouse an exceptionally useful organism in which to study both the protein and the individual globin genes. Early researchers looked to the globin genes as an excellent model in which to examine gene regulation – bountifully expressed and displaying a remarkably consistent pattern of developmental activation and silencing. In parallel with the growth of research into expression of the globin genes, mutations within the β -globin gene were identified as the cause of the β -hemoglobinopathies such as sickle cell disease and β -thalassemia. These lines of enquiry stimulated the development of transgenic mouse models, first carrying individual human globin genes and then substantial human genomic fragments incorporating the multigenic human β -globin locus and regulatory elements. Finally, mice were devised carrying mutant human β -globin loci on genetic backgrounds deficient in the native mouse globins, resulting in phenotypes of sickle cell disease or β -thalassemia. These years of work have generated a group of model animals that display many features of the β -hemoglobinopathies and provided enormous insight into the mechanisms of gene regulation. Substantive differences in the expression of human and mouse globins during development have also come to light, revealing the limitations of the mouse model, but also providing opportunities to further explore the mechanisms of globin gene regulation. In addition, animal models of β -hemoglobinopathies have demonstrated the feasibility of gene therapy for these conditions, now showing success in human clinical trials. Such models remain in use to dissect the molecular events of globin gene regulation and to identify novel treatments based upon the reactivation of developmentally silenced γ -globin. Here, we describe the development of animal models to investigate globin switching and the β -hemoglobinopathies, a field that has paralleled the emergence of modern molecular biology and clinical genetics.

Keywords: β -Hemoglobinopathies, sickle cell disease, globin switching, locus control region, bacterial artificial chromosome, green fluorescent protein

Introduction

The human β -globin locus on chromosome 11 contains the five β -like globin genes, ϵ , γ , δ , and β (Figure 1). Two β -like globin proteins combine with two of the α -like globins (ζ or α) to form the oxygen-carrying hemoglobin (Hb) tetramer of red blood cells (RBCs). Erythropoiesis during mammalian development is characterized by the progressive appearance of distinct populations of erythroid cells expressing stage-specific forms of Hb at defined sites within the embryo. In humans, the earliest (primitive) RBCs are formed in the yolk sac blood islands and contain embryonic Hb (Hb Gower 1; $\zeta_2\epsilon_2$). At approximately 12 weeks of gestation, definitive erythropoiesis

Correspondence: Bradley McColl; Jim Vadolas
Cell and Gene Therapy Laboratory,
Murdoch Childrens Research Institute
Royal Children's Hospital, Flemington
Road, Parkville, VIC - 3052, Australia
Email bradley.mccoll@mcri.edu.au;
jim.vadolas@mcri.edu.au

Figure 1 Developmental expression of the β -like globins in humans and in WT and humanized transgenic mice.

Notes: (A) Diagram of the human (upper) and mouse (lower) β -globin loci. Vertical bars represent DNase I hypersensitive sites in the LCR. Embryonically expressed genes are shown in blue, fetal in green, and adult in red. Switching of the β -like globins in development is shown for (B) human, (C) mice, and (D) human β -like globins in transgenic mice. Values represent the proportion of total β -like globin transcripts detected in erythroid tissue. Note the dual switching events in humans, in contrast to the single mid-gestational switch in WT mice. Note also the mid-gestational switch of human γ - to β -globin expression in transgenic mice.

Abbreviations: LCR, locus control region; WT, wild-type.

commences, marked by RBCs containing fetal Hb (HbF; $\alpha_2\gamma_2$), replacing the embryonic form. Finally, the expression of fetal γ -globin declines postnatally with a concomitant increase of β -globin synthesis, resulting in the production of adult Hb (HbA; $\alpha_2\beta_2$) (Figure 1).^{1,2}

The β -hemoglobinopathies are caused by mutations in the β -globin gene that lead to the production of aberrant HbS (sickle cell disease, SCD) or, in the case of β -thalassemia, insufficient β -globin synthesis causing ineffective erythropoiesis and life-threatening anemia.³ These conditions manifest clinically in the year following birth, when expression of the fetal γ -globin gene is silenced and replaced by the mutated adult β -globin. Globally, more than 300,000 patients are born each year, representing a substantial demand upon health expenditure.³

The October 13th 1956 issue of *Nature* contains two articles that represent the early stages of research into the β -hemoglobinopathies. The first, by Ingram,⁴ describes “A specific chemical difference between the globins of normal human and sickle-cell anemia hemoglobin”. He was following the earlier work of Pauling and Itano,⁵ who analyzed the charge characteristics of normal and sickle Hb, and proposed a genetic basis for the differences. Ingram⁴ examined the tryptic peptides of normal and sickle Hb and identified a single fragment, unique to HbS, that displayed altered charge characteristics. He correctly attributed this to an alteration in the amino acid sequence of the protein and later identified the Glu-Val substitution responsible.⁶ On the pages following Ingram’s article, Halbrecht and Klibanski⁷

published their paper “Identification of a new normal embryonic hemoglobin”. Electrophoretic mobility was used to compare Hb from blood at 10 and 20 weeks of gestational age with samples from newborn umbilical cord and adult. Most significantly, they reported a drop in the concentration of the new Hb, from 83% at 10 weeks gestation to 52% at 20 weeks. With hindsight, it can be seen that they are describing the first Hb switch, when embryonic Hb ($\zeta_2\epsilon_2$) is replaced by fetal HbF ($\alpha_2\gamma_2$).

There is a remarkable confluence in the biology underlying these articles that continues to drive research six decades later. The protective effect of HbF in newborns with SCD had been observed prior to the work of Ingram.⁸ The significance of Hb switching in the context of β -thalassemia began to be recognized with the important work of Fessas and Stamatoyannopoulos⁹ in 1964, describing six families from the Greek Mediterranean region who carried both β -thalassemia and hereditary persistence of fetal Hb (HPFH) traits. HPFH is a nonpathological condition in which the presence of certain genetic polymorphisms leads to incomplete postnatal silencing of the γ -globin gene, resulting in the maintenance of elevated levels of $\alpha_2\gamma_2$ HbF into adulthood. Coinheritance of HPFH with SCD or a β -thalassemia genotype results in milder symptoms due to complementation of the mutant β -globin by the persistent expression of γ -globin. Fessas and Stamatoyannopoulos⁹ observed the mild thalassemia symptoms in individuals displaying elevated HbF and noted that the factor responsible for elevated HPFH “... appears to be very closely linked ... to the gene determining structure of

the β -chain". It is likely that they were examining individuals carrying mutations within the β -globin locus itself that lead to HPFH, genetic variants now known to occur in Mediterranean populations.¹⁰

The clinical significance of Hb switching, along with the desire to understand the developmental regulation of gene expression, has driven the generation of murine *in vivo* model systems to study the human fetal-to-adult Hb switch. These models have provided enormous insight into globin switching as an example of developmental gene regulation, although the process is still incompletely understood. In addition, *in vivo* models of the β -hemoglobinopathies have been created that recapitulate in many aspects the clinical presentation of SCD and β -thalassemia and are valuable tools to investigate novel treatments for these conditions.

Globin switching in the mouse

The laboratory mouse has been the primary model employed for the study of globin switching. Erythropoiesis in the mouse commences in the yolk sac blood islands at ~E7.5, when primitive RBCs appear, expressing the fetal $\epsilon\gamma$ and βH1 genes. By mid-gestation (~E12.5), silencing of the fetal genes is in progress and the adult β^{maj} and β^{min} are becoming expressed.¹¹ It can therefore be seen that developmental β -like globin gene switching is simpler in the mouse than in humans, occurring only once (Figure 1). This fact and the brief gestational period of the mouse (21 days) compared to human suggest that biological differences between the species may limit the utility of the mouse as a model. However, over several decades of research, it has become apparent that the underlying mechanisms regulating the β -globin locus are highly conserved across a very wide range of species, and much has been learned from the rodent. Researchers in the field continue to make use of the mouse, recognizing that with careful interpretation, the rodent is an exceptionally valuable resource, furnishing insights into human biology.

Mouse models of human β -globin switching

Transgenic mice created to investigate human β -globin switching began to be reported in the scientific literature in the mid-1980s. The earliest models examined the expression patterns of individual human globin genes in mice.^{12–14} These studies suggested that the promoter regions immediately upstream of the human globin genes were sufficient to confer developmentally regulated expression in the erythroid lineage, reflective of the pattern of mouse globin switching.

Importantly, however, the levels of expression achieved were low, indicating that additional control elements were necessary for physiological levels of transcription.

Subsequently, models were developed employing the human β -globin locus control region (LCR) fused to either an unrelated reporter gene or one of the human globin genes.^{15–17} These studies demonstrated the capacity of the LCR enhancer to confer high-level erythroid-specific expression of a linked gene. In contrast to the earlier models, the presence of the LCR linked to a single human globin gene apparently overrode the developmental regulation of the transgene, driving the expression of adult human β -globin in embryonic blood.^{16,18}

Subsequent models employed a more physiological arrangement of the transgenic construct, featuring the LCR linked to larger contiguous fragments of the locus, spanning the region from the γ - to the β -globin genes.¹⁸ These transgenic loci showed a remarkable recapitulation of developmentally regulated, high-level globin gene expression. Notably, the large size and complexity of the constructs used in these studies permitted a degree of dissection of the role of individual DNase hypersensitive sites within the LCR; partial abrogation of the LCR had a discernible effect upon expression of genes from the transgenic locus.¹⁸

The result of these experiments using either individual genes linked to the LCR, or more complex constructs featuring multiple globin genes, was to substantially advance our understanding of the principles underlying regulation of the mammalian β -like globins. The existence of globin switching within birds, mice, and humans, and the evolutionary conservation of the locus structure, suggested that the regulatory mechanisms at work may also possess fundamental similarities between species. Previous work in the chicken led to a "one enhancer–two promoter" hypothesis in which competition between gene promoters for interaction with a single enhancer resulted in preferential expression of the interacting gene.^{19,20} The expression of developmentally regulated transcription factors was suggested to account for the stage-specific activation of adult or fetal globin genes. The demonstration that age-related regulation of human globin genes in the mouse was dependent upon the presence of both fetal and adult globin genes strongly indicated that this hypothesis held true for mammals. Furthermore, the developmental regulation of the human locus in mice indicated that the regulatory mechanisms responsible were substantially conserved between rodents and primates.

In addition to the conclusions regarding physiological switching, Enver et al¹⁶ in 1990 made the particularly

insightful suggestion that the competitive switching model explained the phenomenon of deletional HPFH. This group of mutations is characterized by the loss of large segments of the β -globin locus encompassing the δ - and β -genes.^{21,22} Consequently, in the absence of a competing adult β -globin gene, the intact fetal genes maintain high levels of expression throughout the life of the carrier; indeed, they must do so for the carrier to survive. This situation is mimicked by mice carrying a solitary human γ -globin gene linked to the LCR; such animals, lacking an adult β -globin gene in *cis*, express the fetal transgene at high levels in adult blood.¹⁶

The development of yeast and bacterial artificial chromosomes (YACs and BACs, respectively) permitted the propagation and manipulation of large (>100 kb) fragments of DNA. Such technologies made possible the creation of transgenic animals carrying significant stretches of unmodified foreign DNA. Mice harboring YAC fragments of the human β -globin locus further confirmed the developmental regulation of the human globin genes in the rodent, and the presence of all known coding regions and regulatory sequences in their physiological arrangement permitted the results to be interpreted with a greater degree of confidence than those of previous models.^{23–27} Also, the presence of HPFH point mutations within the human locus delivered as a YAC resulted in transgenic mice that recapitulated the delayed globin switching observed in humans.²⁸

The most significant outcome of these studies was the clear demonstration that, in the mouse, expression of the human γ -globin genes commences in the yolk sac with the embryonic $\epsilon\gamma$ and $\beta h1$ -globin genes, rather than in the fetal stage of definitive erythropoiesis as in humans. Additionally, the expression of transgenic human γ -globin continues beyond the time point at which murine $\epsilon\gamma$ and $\beta h1$ are silenced (Figure 1). It should also be noted that the expression of the human β -globin gene from BAC and YAC transgenic loci in the mouse does not reach levels similar to the native murine adult globins (β^{maj} and β^{min}).^{24,27,29} The findings suggest that multiple differences exist between the human and mouse in terms of the regulatory sequences within the human locus and the trans-acting factors responsible for regulation.

To further dissect the regulation of the human locus in the mouse, Ryan et al³⁰ used a series of human minilocus constructs consisting of the LCR linked to the γ - and β -globin genes, and harboring progressive deletions of the region immediately upstream of the γ transcriptional start site. Transgenic mice carrying deletions of upstream sequences proximal to the γ -globin gene showed alterations to the developmental regulation of the genes, with human β -globin

appearing preferentially in the yolk sac, and loss of γ -globin transcripts in the fetal liver. Further analysis of the deleted region revealed a CACCC sequence motif in the γ promoter, the loss of which was responsible for the aberrant regulation of the transgenes.³⁰ Such motifs are binding sites for the KLF1 transcription factor known to be associated with the γ - to β -globin switch,³¹ supporting the hypothesis that while high-level transcription of individual globin genes is driven by the LCR, developmental specificity is conferred by a combination of transcription factors and promoter sequence elements.

Observation of globin switching in viable cells was achieved through the creation of transgenic animals carrying fluorescent reporter constructs. Placing the coding sequence of green fluorescent protein (GFP) under the control of the human ϵ -globin promoter and a mini-LCR resulted in labeling of the primitive erythroblasts. Examination of the fluorescently tagged cells revealed changes in surface antigen expression as the cells matured and enucleated, demonstrating the utility of this approach for sensitive labeling of erythroid cells.³²

Modification of β -globin BACs to introduce fluorescent reporter genes in place of globin-coding sequences within the native genomic loci was used to produce transgenic animals with single (γ -GFP/GG mouse)³³ or dual (γ -GFP and β -dsRed)³⁴ reporters. GFP fluorescence traced the developmental locations of erythropoiesis (yolk sac, aorta-gonad-mesonephros, and fetal liver) in the GG mouse and progressive silencing of the reporter gene, as anticipated (Figure 2). Also, in vitro drug treatment of fetal liver erythroid cells demonstrated the utility of such cells for high-throughput screening of compounds for inducers of HbF.³³

Mouse deletion models of β -thalassemia

The first published model of β -thalassemia in the mouse was a spontaneously occurring mutation identified on the basis of reduced expression of the β^{maj} gene.³⁵ Mice homozygous for the mutation (*Hbb^{th-1}*) were viable but lacked detectable β^{maj} protein and showed evidence of a compensatory increase in expression of the β^{min} gene. Hematological characteristics were reminiscent of thalassemia intermedia in the homozygotes, whereas heterozygotes showed normal blood parameters. A subsequent analysis of the *Hbb^{th-1}* mouse suggested that, in comparison to human, the decreased solubility and lack of proteolytic degradation of free mouse α -globin contributed to the severity of the *Hbb^{th-1}* phenotype.³⁶ Interestingly, a targeted disruption of the same β^{maj}

Figure 2 Visualization of sites of erythropoiesis using the $G\gamma$ -eGFP fluorescently tagged BAC reporter mouse.

Notes: (A) The human β -globin locus, carried on a BAC, was modified via recombineering to replace the $G\gamma$ and $A\gamma$ genes with that of eGFP, under the control of the $G\gamma$ promoter. (B) Transgenic mouse embryos carrying the modified β -globin locus are shown under visible light (upper) and fluorescence illumination (lower). eGFP fluorescence marks the sites of yolk sac blood islands at E7.5, the aorta-gonad-mesonephros and fetal liver at E10.5, and the fetal liver at E12.5 (arrows).³³

Abbreviations: eGFP, enhanced green fluorescent protein; BAC, bacterial artificial chromosome.

gene (Hbb^{th-2}) by insertion of a selectable neomycin cassette resulted in a lethal thalassemia in homozygotes at late gestation or shortly after birth.³⁷ The timing of lethality in the mice, shortly after the switch from fetal to adult β -globin expression, mirrors the postnatal appearance of symptoms in human patients as switching progresses. The authors suggest the phenotypic difference between the Hbb^{th-1} and Hbb^{th-2} mice resulted from the addition to the locus of the TK promoter within the targeting cassette. Competition for interaction with the LCR occurred between the β^{maj} , β^{min} , and TK promoters; however, only the β^{min} gene transcribed a functional β -globin gene. Lower levels of β^{min} expression were observed in Hbb^{th-2} than Hbb^{th-1} , suggesting that this unintended modulation of LCR activity was responsible for the severe β -thalassemic phenotype, further supporting the one enhancer–two promoter competitive model of globin switching.

Further gene-targeting strategies lead to the creation of mice lacking both the adult β^{maj} and β^{min} genes, recapitulating the severe β^0 -thalassemia phenotype (Hbb^0 and Hbb^{th-3} mice).^{38,39} As with the Hbb^{th-2} mutation, homozygous deletion of both adult genes was lethal at either late gestation or shortly after birth.

Significantly, no upregulation of the embryonic $\epsilon\gamma$ and $\beta h1$ genes was detected in the homozygous deletion animals, unlike the elevated expression of the human γ -globin genes

observed in deletional HPFH. This observation indicates that the murine embryonic and adult globin genes are not in direct competition for the LCR enhancer activity. Instead it may be that the interaction with the LCR is determined by developmentally regulated transcription factors that bind specifically to either the embryonic or adult promoters, but not both. Under this hypothesis, loss of the adult genes does not result in an increased expression of the embryonic genes because the trans-acting factors responsible for positioning the adult promoters at the LCR fail to recognize the embryonic promoters.

Although homozygous knockout mice were not viable, heterozygotes survived, albeit with phenotypes remarkably reminiscent of severe β -thalassemic patients, in line with the conserved structure and function of Hb between the two species. RBC Hb concentrations were reduced, cells showed microcytosis and anisopoikilocytosis, hematocrit was reduced, and reticulocytes were elevated. In addition, mice showed systemic effects similar to those observed in the clinic – splenomegaly due to extramedullary erythropoiesis, bone malformation, and iron deposition in multiple tissues including the liver (Figure 3). The Hbb^{th-3} mice exhibit reduced expression of the iron-regulatory hormone hepcidin, a phenomenon observed in human patients also.⁴⁰ Repression of hepcidin stimulates duodenal iron absorption, a counter-intuitive occurrence given the iron overloaded phenotype of Hbb^{th-3} mice and β -thalassemia patients. This observation indicates that the Hbb^{th-3} mouse may be useful to investigate the more subtle defects of iron metabolism in β -thalassemia.

Of particular significance in the characterization of the Hbb^{th-3} mouse was the demonstration that the homozygous deletion genotype could be rescued by crossing with mice expressing high levels of human hemoglobin A (HbA).^{38,41} This confirmed the structural and functional conservation of Hb between the species, laying the groundwork for future models expressing exclusively human globin genes in conjunction with genuine SCD or β -thalassemia mutations.

Humanized murine models of β -thalassemia

Although deletion of the mouse β -globin genes resulted in phenotypes similar to the human β -thalassemias, such models lacked the human genomic sequences responsible for the condition. Therefore, therapeutic strategies intended to correctly splice mutant transcripts, or to induce expression of the γ -globins could not be tested in these animals.

The prospect of remedying splicing defects leads to the development of the Hbb^{th-4} mouse, incorporating a human

Figure 3 Systemic iron accumulation in the *Hbb*^{th-3/+} β-thalassemic mouse.

Notes: Sections of spleen, liver, and kidney from WT or *Hbb*^{th-3/+} heterozygous littermates were stained with Prussian blue to visualize iron deposits. The substantial presence of positive staining in the *Hbb*^{th-3/+} samples, indicative of the dysregulated iron metabolism associated with the β-thalassemic phenotype (First described by Yang et al³⁹).

Abbreviation: WT, wild-type.

β-globin gene integrated into the mouse locus in place of the deleted adult globin genes of *Hbb*^{th-3}. The integrated human gene carried the IVS-2-654 mutation that generates an incorrectly spliced primary transcript, resulting in heterozygotes with features of β-thalassemia intermedia, while homozygous mice were not viable.⁴² This model has been employed to demonstrate repair of the aberrant splicing in vivo and improvement of the thalassemic symptoms, by intravenous delivery of a splice-selecting oligonucleotide. The splice-selecting oligonucleotide employed was a morpholino oligomer designed to block the mutant splice site and force the correct splicing event.⁴³ When combined with α-globin knockdown to further normalize α:β globin ratios, splicing repair achieved substantial improvement in erythropoiesis.⁴⁴

More extensively humanized models were created through the use of bacterial recombineering techniques to introduce specific β-thalassemia mutations into human genomic fragments propagated as BACs, and the mutated loci used to generate transgenic animals. The simplicity and fidelity of recombineering permitted the generation of several genomic constructs featuring common β-thalassemia mutations (HbE, IVS1-110, and CD 41/42)^{45–49} and the creation of humanized transgenic mice incorporating mutated loci.^{50,51} When carried

on a genetic background of heterozygous or homozygous deletion of the mouse adult globin genes, these models could be considered to represent a near optimal recreation of the human condition, within the limits imposed by interspecies variation. Significantly, the aberrant splicing events of the IVS1-110 and HbE mutations are recapitulated in the mouse; this finding demonstrates the functional conservation of transcript splicing between species and the suitability of the murine model to investigate methods to correct the process in humans (Figure 4).^{49,51}

One further model of severe β-thalassemia was created through targeted insertion of a human $\Delta\gamma\text{-}\beta^0$ (IVS1-1) cassette in place of the murine adult β^{maj} and β^{min} genes.⁵² Unsurprisingly, heterozygotes displayed characteristics of β-thalassemia in their RBC indices as well as splenic and hepatic erythropoiesis. The authors reported an extended expression of the human $\Delta\gamma$ gene, reminiscent of the two-stage switching in humans, and showed in a separate publication expression of the knocked-in $\Delta\gamma$ gene in the definitive erythroid lineage.⁵³ Regardless, homozygous $\Delta\gamma\text{-}\beta^0$ pups did not survive to birth, dying at ~E18.5 due to severe anemia.⁵²

Transgenic SCD models

Following the demonstration that transgenic mice expressing the human α- and β-globin genes produced functional human HbA,⁴¹ humanized murine models of SCD were created. Expression of the mutated human β^S-globin resulted in minimal hematological changes and little sickling in vivo, reminiscent of the heterozygous sickle cell trait and presumably due to the compensatory effect of the native mouse β-globins.^{54,55} More extensive SCD phenotypes were achieved by expression of β^S variants incorporating additional mutations known to enhance the severity of the sickle phenotype (Antilles [β²³Ile] and D-Punjab [β¹²¹Gln], the β^{SAD} mouse) and crossing the human α- and β^S transgenes onto a β-thalassemic background.^{56–58} Severe anemia, in vivo sickling of RBCs, and mortality in response to hypoxia was the result. Of note was the frequent occurrence of lethality in utero, due to the mid-gestational switch to expression of adult globins that occurs in the mouse. The timing of this event resulted in a fetal expression of the sickling phenotype, whereas in humans the postnatal switch from γ- to β-globin masks the presence of the sickle cell mutation until after birth.

Two further models sought to replicate SCD as extensively as possible, by generating mice carrying the genes for human α- and β^S-globin on a genetic background deficient for the murine globins.^{59,60} One⁶⁰ or both γ-globin genes⁵⁹ were incorporated into these models in an attempt to avert

Figure 4 Recapitulation of IVSI-110 β -thalassemia splicing defect in BAC transgenic mice.

Notes: (A) BAC recombineering was used to modify the 180-kb WT human β -globin locus so as to incorporate the IVSI-110 splicing mutation within the β -globin gene (B). HPLC analysis of globin profiles from (C) WT mice showed approximately equal proportions of murine α - and β -globin ($\mu\alpha$, $\mu\beta$), whereas human β -globin made up approximately 10% of the total globins in WT mice carrying the native human β -globin locus ($\mu\beta$, shown in red) (D). (E) Heterozygous *Hbb*^{th-3/+} mice carrying the WT human β -globin locus mice expressed higher levels of human β -globin, whereas (F) the presence of the IVSI-110 splicing mutation in the human β -globin locus abrogated expression substantially on the same β -thalassemic genetic background.

Abbreviations: WT, wild-type; BAC, bacterial artificial chromosome.

the gestational lethality observed previously, by taking advantage of the antisickling properties of the γ -globins and the extended expression of the human genes into the latter stages of murine fetal development. Frequent hypoxic death was observed in the hours following birth,⁵⁹ presumably due to severe sickle crisis induced by hypoxia in the period when newborn lungs commence functioning independently. Surviving mice reached adulthood expressing exclusively human HbS and showed a SCD phenotype closely paralleling that of human patients – in vivo sickling of RBCs in response to hypoxia, anemia with reduced hematocrit, and increased reticulocytes. The mice also exhibited the systemic symptoms of the condition, including increased weight of heart and spleen, and splenic erythropoiesis.^{59,60}

Gene therapy in the mouse

As can be seen, the globin field has accumulated a panoply of mouse models intended to examine the mechanisms underlying globin switching and to recreate genetic perturbations of globin synthesis (summarized in Table 1). As with all models, the value of the mouse lies in the degree to which it

recapitulates the functioning of human biology. The structural and functional conservation of the β -globins between mice and humans is demonstrated by the formation of functional human Hb in transgenic mice and the recreation of the symptoms of the β -hemoglobinopathies in mice carrying SCD and β -thalassemia genotypes. In addition, human β - and mouse α -globin proteins can combine to form functional chimeric Hb. This functional conservation is essential for testing gene therapy vectors expressing the human protein in mouse models of the β -hemoglobinopathies.

Early gene therapy research examined expression of the human β -globin gene when driven by minimal LCR constructs in order to determine what sequence elements are essential to drive high-level transgene expression.⁶¹ Similar work has been undertaken to determine the levels of γ -globin expression that are sufficient for therapeutic effects.⁶² A genuine strategy for gene therapy of the β -hemoglobinopathies was first successfully demonstrated in the *Hbb*^{th-3/+} mouse, using a lentivirus for ex vivo delivery of a functional β -globin minigene into bone marrow hematopoietic stem cells (HSCs) followed by transplantation of the modified cells into *Hbb*^{th-3/+}

Table 1 Summary of murine models of β -thalassemia and sickle cell disease

Model	Transgene description	Phenotype	Reference
β-Thalassemia models			
<i>Hbb^{th-1}</i>	EthylNitrosourea-induced deletion of β^{maj} gene	Thalassemia intermedia (homozygotes)	35
<i>Hbb^{th-2}</i>	Targeted disruption of β^{maj} gene	Homozygous lethal	37
<i>Hbb⁰</i>	Targeted disruption of β^{maj} and β^{min} genes	Severe thalassemia (heterozygotes); homozygous lethal	38
<i>Hbb^{th-3}</i>	Targeted disruption of β^{maj} and β^{min} genes	Severe thalassemia (heterozygotes); homozygous lethal	39
<i>Hbb^{th-4}</i>	Humanized model; murine β^{maj} and β^{min} genes replaced by the human $\beta\text{IVS-2-654}$	Severe thalassemia (heterozygotes); homozygous lethal	42
DH Δ 4bp	BAC transgenic; human β -globin locus carrying codons 41–42 4-bp deletion (–TTCT) on <i>Hbb^{th-3}</i> background	Thalassemia intermedia (<i>Hbb^{th-3/+}</i> background)	50
<i>huβ^E</i>	BAC transgenic; human β -globin locus carrying HbE mutation on <i>Hbb^{th-3}</i> background	Moderates <i>Hbb^{th-3/+}</i> ; rescues lethality of <i>Hbb^{th-3/th-3}</i> homozygotes	49
IVSI-110 β	BAC transgenic; human β -globin locus carrying IVSI-110 mutation on <i>Hbb^{th-3}</i> background	Recapitulates splicing defect; slight correction of <i>Hbb^{th-3/+}</i>	51
$\gamma\beta^0$	Human $\Lambda\gamma\text{-}\beta^0$ (IVSI.IG-A) cassette integrated in place of murine β^{maj} and β^{min} genes	Thalassemia intermedia (heterozygotes), lethal in homozygotes	52
Sickle cell disease models			
HbS/ β -thal	Human LCR- α -globin and LCR- β^S -globin cassettes carried on <i>Hbb^{th-1}</i> background	SCD phenotype enhanced on <i>Hbb^{th-1/+}</i>	54
$\alpha\alpha\beta^S$	Two human αI genes and a single β^S gene under control of a truncated human β -globin LCR	Mild, similar to sickle trait	55
$\alpha\beta^S$ Antilles	Human α2 -globin and β^S Antilles-globin variant ($\beta^{23}\text{Ile}$), each linked to individual LCR HSII fragments	In vivo sickling upon hypoxia	56
β^{SAD}	Human α2 -globin linked to a human β -globin LCR; human β^{SAD} -globin gene carrying Antilles and Hb D-Punjab ($\beta^{121}\text{Gln}$) variants linked to a human β -globin LCR	Severe SCD and frequent lethality when crossed to <i>Hbb^{th-1/+}</i>	57,87
Berkeley mouse	Mini-LCR expressing human αI , γ , δ , β^S globins on a murine α - and β -globin-deficient background	Severe SCD, multiple organs affected	59
HbS	Human mini-LCR expressing human αI , γ , β^S globins on a murine α - and β -globin-deficient background	Severe SCD, multiple organs affected.	60

Abbreviations: SCD, sickle cell disease; LCR, locus control region; Hb, hemoglobin; BAC, bacterial artificial chromosome.

recipient animals.⁶³ Upon reconstitution of the hematopoietic system in vivo, *Hbb^{th-3/+}* stem cells carrying the lentiviral vector (LV) provided a substantial improvement in multiple symptoms – increased hematocrit and Hb concentrations – while reticulocytes and RBC morphological abnormalities associated with the thalassemia phenotype were reduced. Long-term studies of the LV-treated animals showed sustained improvement in Hb levels and reduced hepatic iron accumulation.⁶⁴ The same study compared the expression of the β -globin transgene in vectors featuring minimal or more extensive LCR sequences; unsurprisingly, larger LCR fragments were more effective drivers of expression.

A separately developed LV achieved extensive rescue of the SCD phenotype in β^{SAD} and BERK mice through the expression of a variant β -globin created to inhibit the Hb polymerization of the condition.⁶⁵ Significant reduction of

RBC sickling was observed, along with improvements in hematological parameters. The authors noted the necessity for high viral titers to achieve the pancellular expression of the transgene necessary to fully ameliorate the SCD phenotype.

Further gene transfer studies confirmed the utility of LVs for the delivery of β -globin transgenes into HSCs and the subsequent improvement in symptoms in SCD and β -thalassemic mice following engraftment of transduced cells.^{66,67} Significantly, long-term analysis of mice following gene transfer therapy confirmed the capacity of LVs to maintain expression of β - or γ -globin transgenes, an essential prerequisite for clinical success.^{64,68,69} Such vectors have now passed into human trials, where they have achieved relief of acute and chronic symptoms of β -thalassemia and long-term transfusion independence.^{70,71} Further trials in β -thalassemia and SCD patients are ongoing.⁷²

Moving beyond classical viral gene replacement therapy, the development of induced pluripotent stem cells raised the possibility of repairing the genetic defect in cells derived from individual patients. The repaired cells might then be differentiated *in vitro* into HSCs and returned to the patient where they will give rise to RBCs expressing the repaired β -globin gene. Such an approach was shown to be possible in a SCD mouse, albeit in the short term as the field has yet to achieve the generation of truly long-term repopulating HSCs from induced pluripotent stem cells.⁷³

Animal models to manipulate globin switching

Examination of β -globin gene switching in the mouse has provided tremendous advances in our understanding of gene regulation, a primary driver of early investigations of the locus. The fundamental processes at work in widely divergent species are sufficiently similar to ensure that study of the mouse, and even the chicken, has been a source of enormous insight into fundamental human biology. Such work continues to date, with current interest focusing upon chromatin and epigenetic regulation as components of the switching process.

The promise of gene therapy to provide a cure for the β -hemoglobinopathies now seems close to becoming a reality, at least technically. At present, however, gene therapy fails to deliver universal treatment for nontechnical reasons, specifically those relating to economics. Clinical gene therapy is a technologically demanding field, restricted to a small number of centers worldwide. The costs associated with stem cell transfer are substantial, with single treatments costing in excess of 100,000–200,000 USD,⁷⁴ while the first gene therapy treatment in the western world for lipoprotein lipase deficiency costs around \$1 million per treatment.⁷⁵ These facts collide with the reality of the worldwide distribution of SCD and β -thalassemia patients. World Health Organization figures demonstrate that the global burden of births affected by these conditions is carried primarily by African populations, located in regions where annual per capita expenditure on health is one to two orders of magnitude lower than in the most developed nations.⁷⁶ This economic reality therefore demands cheaper therapies, driving the field to search for small molecules capable of reactivating γ -globin expression and suitable for long-term administration. At present, hydroxyurea is the only agent approved for reactivation of γ -globin expression in SCD and β -thalassemia; however, responses are variable, and there are no known biomarkers to definitively predict response.⁷⁷

The use of mouse models to search for strategies and compounds to reactivate γ -globin expression is predicated upon the assumption that the regulatory mechanisms responsible

are substantially conserved between the species. The flaws in this assumption relate in this case to the single developmental β -globin switch in rodents and the lack of a fetal stage Hb (HbF). This difference is most clearly apparent in BAC and YAC transgenic mice, where the native arrangement of large genomic transgenes permits researchers to discount the possibility of artifacts resulting from the use of minimal constructs with reorganized or absent regulatory elements.

In humans, the expression of γ -globin commences with the onset of definitive erythropoiesis, in concert with silencing of the ϵ -globin gene. β -Globin BAC and YAC transgenic mice reveal the evolutionary relationship between murine β h1 and human γ -globin genes, in that the two are expressed in parallel in the mouse, commencing in the primitive erythroid precursors of the yolk sac.^{23,25} However, while β h1-globin expression is silenced by murine mid-gestation, when definitive erythropoiesis is occurring in the fetal liver, transgenic mice exhibit substantial human γ -globin transcription in erythroid tissue at this time point. The earlier onset of γ -globin expression and the delay in silencing relative to ϵ y and β h1-globin have been observed in multiple independently generated models, confirming the biological divergence between the two species (Figure 1).

Examination of this phenomenon further illustrated the regulation of the human embryonic γ -globin gene as a fetal/embryonic gene in the mouse. Separation of primitive and definitive erythroid cells from E13.5 mice carrying a human β -globin YAC transgene demonstrated substantial elevation of γ -globin expression in the primitive cells relative to the definitive.⁷⁸ Microscopic examination of fetal livers revealed the presence of nucleated primitive erythroblasts expressing γ -globin at E13.5, whereas expression was largely absent in enucleated definitive cells at the same time point. Interestingly, a small proportion of adult RBCs contain transgenic γ -globin protein, similar to the infrequent F-cells detected in adult humans and demonstrating that the γ -globin gene is also expressed to some degree in murine definitive erythroid tissue.²³ Expression of γ -globin was also observed in the definitive erythroid lineage of the $\Lambda\gamma$ - β knock-in mouse.⁵³

These interspecies differences present a difficulty to researchers seeking to use the mouse as a model to dissect the regulation of γ -globin and devise new therapies targeting the process. Encouragingly, reports abound in the literature describing regulators of γ -globin that demonstrate conserved function in both mouse models of globin switching and primary human erythroid cells.^{31,79–82} Such findings demonstrate the conservation of many aspects of globin switching between human and mouse, and, accordingly, significant efforts have been put in place to devise reporter animals

and to conduct chemical screens for novel inducers of HbF in mouse cells.^{33,34,83}

To move beyond the mouse, some researchers have made use of the baboon to study globin switching in primates. Although the baboon closely reiterates the structure and switching of the human β -globin locus, the inherent complexities of primate research have limited the number of such studies. Nevertheless, valuable insights have been gained, particularly in preclinical testing of novel therapeutic inducers.^{84–86}

Conclusion

The development and availability of biological resources and sophisticated genomic technologies to manipulate the mouse genome has enhanced our understanding of the regulatory network responsible for globin expression. Importantly, a better understanding of these developmental events may allow the identification of key targets for therapeutic intervention. The mouse has been shown to be a physiologically relevant mammalian system, which recreates specific disease phenotypes associated with β -hemoglobinopathies. Given the complex pathophysiology of β -hemoglobinopathies and our current incomplete understanding of globin gene regulation in humans, the mouse model will continue to provide valuable insight into the genetic basis of human disease. Despite these decades of work and the elucidation of the molecular basis of SCD and β -thalassemia, improvement in the clinical management of these conditions has been slow. The challenge now is to move beyond the creation of model systems and to identify novel pharmacological and genetic approaches that are suitable for widespread application to the multitude of patients worldwide who are living with the β -hemoglobinopathies.

Note concerning gene nomenclature. The authors have used non-standard nomenclature for gene names, reflecting that which is in common usage amongst researchers in the globin field. For clarity the standardised gene names are as follows: Human β -globin, HBB; δ , HBD; γ , HBG1; γ , HBG2; ϵ , HBE; ζ , HBZ; α , HBA1 & HBA2. Murine β^{maj} -globin, Hbb-b1; β^{min} , Hbb-b2; β^{h1} , Hbb-bh1; $\epsilon\gamma$, Hbb-y.

Acknowledgments

This work was supported by the Australian National Health and Medical Research Council, the Murdoch Childrens Research Institute, the Victorian Government's Operational Infrastructure Support Program, and Thalassemia Australia.

Disclosure

The authors report no conflicts of interest in this work.

References

- Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. *Cell*. 2008;132(4):631–644.
- Baron MH, Isern J, Fraser ST. The embryonic origins of erythropoiesis in mammals. *Blood*. 2012;119(21):4828–4837.
- Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. *Blood*. 2010;115(22):4331–4336.
- Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. *Nature*. 1956;178(4537):792–794.
- Pauling L, Itano HA. Sickle cell anemia a molecular disease. *Science*. 1949;110(2865):543–548.
- Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. *Nature*. 1957;180(4581):326–328.
- Halbrecht I, Klibanski C. Identification of a new normal embryonic haemoglobin. *Nature*. 1956;178(4537):794–795.
- Watson J. The significance of the paucity of sickle cells in newborn Negro infants. *Am J Med Sci*. 1948;215(4):419–423.
- Fessas P, Stamatiyannopoulos G. Hereditary persistence of fetal hemoglobin in Greece: a study and a comparison. *Blood*. 1964;24(3):223–240.
- Kulozik AE, Yarwood N, Jones RW. The Corfu delta beta zero thalassemia: a small deletion acts at a distance to selectively abolish beta globin gene expression. *Blood*. 1988;71(2):457–462.
- Sankaran VG, Xu J, Orkin SH. Advances in the understanding of haemoglobin switching. *Br J Haematol*. 2010;149(2):181–194.
- Chada K, Magram J, Raphael K, Radice G, Lacy E, Costantini F. Specific expression of a foreign beta-globin gene in erythroid cells of transgenic mice. *Nature*. 1985;314(6009):377–380.
- Magram J, Chada K, Costantini F. Developmental regulation of a cloned adult beta-globin gene in transgenic mice. *Nature*. 1985;315(6017):338–340.
- Chada K, Magram J, Costantini F. An embryonic pattern of expression of a human fetal globin gene in transgenic mice. *Nature*. 1986;319(6055):685–689. doi:10.1038/319685a0.
- Grosveld F, van Assendelft GB, Greaves DR, Kollias G. Position-independent, high-level expression of the human beta-globin gene in transgenic mice. *Cell*. 1987;51(6):975–985.
- Enver T, Raich N, Ebens AJ, Papayannopoulou T, Costantini F, Stamatiyannopoulos G. Developmental regulation of human fetal-to-adult globin gene switching in transgenic mice. *Nature*. 1990;344(6264):309–313.
- Stamatiyannopoulos G, Josephson B, Zhang JW, Li Q. Developmental regulation of human gamma-globin genes in transgenic mice. *Mol Cell Biol*. 1993;13(12):7636–7644.
- Behringer RR, Ryan TM, Palmiter RD, Brinster RL, Townes TM. Human gamma- to beta-globin gene switching in transgenic mice. *Genes Dev*. 1990;4(3):380–389.
- Choi OR, Engel JD. Developmental regulation of beta-globin gene switching. *Cell*. 1988;55(1):17–26.
- Nickol JM, Felsenfeld G. Bidirectional control of the chicken beta- and epsilon-globin genes by a shared enhancer. *Proc Natl Acad Sci U S A*. 1988;85(8):2548–2552.
- Forget BG. Molecular basis of hereditary persistence of fetal hemoglobin. *Ann NY Acad Sci*. 1998;850:38–44.
- Bank A, O'Neill D, Lopez R, et al. Role of intergenic human gamma-delta-globin sequences in human hemoglobin switching and reactivation of fetal hemoglobin in adult erythroid cells. *Ann NY Acad Sci*. 2005;1054:48–54.
- Peterson KR, Clegg CH, Huxley C, et al. Transgenic mice containing a 248-kb yeast artificial chromosome carrying the human beta-globin locus display proper developmental control of human globin genes. *Proc Natl Acad Sci U S A*. 1993;90(16):7593–7597.
- Porcu S, Kitamura M, Witkowska E, et al. The human beta globin locus introduced by YAC transfer exhibits a specific and reproducible pattern of developmental regulation in transgenic mice. *Blood*. 1997;90(11):4602–4609.

25. Strouboulis J, Dillon N, Grosveld F. Developmental regulation of a complete 70-kb human beta-globin locus in transgenic mice. *Genes Dev.* 1992;6(10):1857–1864.
26. Gaensler KM, Kitamura M, Kan YW. Germ-line transmission and developmental regulation of a 150-kb yeast artificial chromosome containing the human beta-globin locus in transgenic mice. *Proc Natl Acad Sci U S A.* 1993;90(23):11381–11385.
27. Kaufman RM, Pham CT, Ley TJ. Transgenic analysis of a 100-kb human beta-globin cluster-containing DNA fragment propagated as a bacterial artificial chromosome. *Blood.* 1999;94(9):3178–3184.
28. Peterson KR, Li QL, Clegg CH, et al. Use of yeast artificial chromosomes (YACs) in studies of mammalian development: production of beta-globin locus YAC mice carrying human globin developmental mutants. *Proc Natl Acad Sci U S A.* 1995;92(12):5655–5659.
29. Vadolas J, Warden H, Bosmans M, et al. Transgene copy number-dependent rescue of murine beta-globin knockout mice carrying a 183 kb human beta-globin BAC genomic fragment. *Biochim Biophys Acta.* 2005;1728(3):150–162.
30. Ryan TM, Sun CW, Ren J, Townes TM. Human gamma-globin gene promoter element regulates human beta-globin gene developmental specificity. *Nucleic Acids Res.* 2000;28(14):2736–2740.
31. Tallack MR, Perkins AC. Three fingers on the switch: Krüppel-like factor 1 regulation of γ -globin to β -globin gene switching. *Curr Opin Hematol.* 2013;20(3):193–200.
32. Fraser ST, Isern J, Baron MH. Maturation and enucleation of primitive erythroblasts during mouse embryogenesis is accompanied by changes in cell-surface antigen expression. *Blood.* 2007;109(1):343–352.
33. McColl B, Kao BR, Lourthai P, et al. An in vivo model for analysis of developmental erythropoiesis and globin gene regulation. *FASEB J Off Publ Fed Am Soc Exp Biol.* 2014;28(5):2306–2317.
34. Papadopoulos P, Gutiérrez L, van der Linden R, et al. A dual reporter mouse model of the human β -globin locus: applications and limitations. *PloS One.* 2012;7(12):e51272.
35. Skow LC, Burkhart BA, Johnson FM, et al. A mouse model for beta-thalassemia. *Cell.* 1983;34(3):1043–1052.
36. Rouyer-Fessard P, Leroy-Viard K, Domenget C, Mrad A, Beuzard Y. Mouse beta thalassemia, a model for the membrane defects of erythrocytes in the human disease. *J Biol Chem.* 1990;265(33):20247–20251.
37. Shehee WR, Oliver P, Smithies O. Lethal thalassemia after insertional disruption of the mouse major adult beta-globin gene. *Proc Natl Acad Sci U S A.* 1993;90(8):3177–3181.
38. Ciavatta DJ, Ryan TM, Farmer SC, Townes TM. Mouse model of human beta zero thalassemia: targeted deletion of the mouse beta maj- and beta min-globin genes in embryonic stem cells. *Proc Natl Acad Sci U S A.* 1995;92(20):9259–9263.
39. Yang B, Kirby S, Lewis J, Detloff PJ, Maeda N, Smithies O. A mouse model for beta 0-thalassemia. *Proc Natl Acad Sci U S A.* 1995;92(25):11608–11612.
40. Weizer-Stern O, Adamsky K, Amariglio N, et al. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models. *Am J Hematol.* 2006;81(7):479–483.
41. Behringer RR, Ryan TM, Reilly MP, et al. Synthesis of functional human hemoglobin in transgenic mice. *Science.* 1989;245(4921):971–973.
42. Lewis J, Yang B, Kim R, et al. A common human beta globin splicing mutation modeled in mice. *Blood.* 1998;91(6):2152–2156.
43. Svasti S, Suwanmanee T, Fucharoen S, et al. RNA repair restores hemoglobin expression in IVS2-654 thalassemic mice. *Proc Natl Acad Sci U S A.* 2009;106(4):1205–1210.
44. Xie SY, Li W, Ren ZR, Huang SZ, Zeng F, Zeng YT. Correction of β 654-thalassaemia mice using direct intravenous injection of siRNA and antisense RNA vectors. *Int J Hematol.* 2011;93(3):301–310.
45. Jamsai D, Nefedov M, Narayanan K, et al. Insertion of common mutations into the human beta-globin locus using GET Recombination and an EcoRI endonuclease counterselection cassette. *J Biotechnol.* 2003;101(1):1–9.
46. Nefedov M, Williamson R, Ioannou PA. Insertion of disease-causing mutations in BACs by homologous recombination in Escherichia coli. *Nucleic Acids Res.* 2000;28(17):E79.
47. Jamsai D, Orford M, Nefedov M, Fucharoen S, Williamson R, Ioannou PA. Targeted modification of a human beta-globin locus BAC clone using GET recombination and an I-SceI counterselection cassette. *Genomics.* 2003;82(1):68–77.
48. Jamsai D, Orford M, Fucharoen S, Williamson R, Ioannou PA. Insertion of modifications in the beta-globin locus using GET recombination with single-stranded oligonucleotides and denatured PCR fragments. *Mol Biotechnol.* 2003;23(1):29–36.
49. Jamsai D, Zaibak F, Vadolas J, et al. A humanized BAC transgenic/knockout mouse model for HbE/beta-thalassemia. *Genomics.* 2006;88(3):309–315.
50. Jamsai D, Zaibak F, Khongnium W, et al. A humanized mouse model for a common beta0-thalassemia mutation. *Genomics.* 2005;85(4):453–461.
51. Vadolas J, Nefedov M, Warden H, et al. Humanized beta-thalassemia mouse model containing the common IVS1-110 splicing mutation. *J Biol Chem.* 2006;281(11):7399–7405.
52. Huo Y, McConnell SC, Liu SR, et al. Humanized mouse model of cooley's anemia. *J Biol Chem.* 2009;284(8):4889–4896.
53. McConnell SC, Huo Y, Liu S, Ryan TM. Human globin knock-in mice complete fetal-to-adult hemoglobin switching in postnatal development. *Mol Cell Biol.* 2011;31(4):876–883.
54. Ryan TM, Townes TM, Reilly MP, et al. Human sickle hemoglobin in transgenic mice. *Science.* 1990;247(4942):566–568.
55. Greaves DR, Fraser P, Vidal MA, et al. A transgenic mouse model of sickle cell disorder. *Nature.* 1990;343(6254):183–185.
56. Rubin EM, Witkowska HE, Spangler E, et al. Hypoxia-induced in vivo sickling of transgenic mouse red cells. *J Clin Invest.* 1991;87(2):639–647.
57. Trudel M, Saadane N, Garel MC, et al. Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD. *EMBO J.* 1991;10(11):3157–3165.
58. Fabry ME, Sengupta A, Suzuka SM, et al. A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity. *Blood.* 1995;86(6):2419–2428.
59. Pászty C, Brion CM, Mancini E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. *Science.* 1997;278(5339):876–878.
60. Ryan TM, Ciavatta DJ, Townes TM. Knockout-transgenic mouse model of sickle cell disease. *Science.* 1997;278(5339):873–876.
61. Ellis J, Pasceri P, Tan-Un KC, et al. Evaluation of beta-globin gene therapy constructs in single copy transgenic mice. *Nucleic Acids Res.* 1997;25(6):1296–1302.
62. Nishino T, Cao H, Stamatoyannopoulos G, Emery DW. Effects of human gamma-globin in murine beta-thalassaemia. *Br J Haematol.* 2006;134(1):100–108.
63. May C, Rivella S, Callegari J, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. *Nature.* 2000;406(6791):82–86.
64. May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. *Blood.* 2002;99(6):1902–1908.
65. Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. *Science.* 2001;294(5550):2368–2371.
66. Puthenveetil G, Scholes J, Carbonell D, et al. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. *Blood.* 2004;104(12):3445–3453.
67. Perumbeti A, Higashimoto T, Urbinati F, et al. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. *Blood.* 2009;114(6):1174–1185.
68. Miccio A, Cesari R, Lotti F, et al. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. *Proc Natl Acad Sci U S A.* 2008;105(30):10547–10552.

69. Pestina TI, Hargrove PW, Jay D, Gray JT, Boyd KM, Persons DA. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. *Mol Ther J Am Soc Gene Ther*. 2009;17(2):245–252.
70. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGAA2 activation after gene therapy of human β -thalassaemia. *Nature*. 2010;467(7313):318–322.
71. Negre O, Bartholomae C, Beuzard Y, et al. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β -thalassaemia and sickle cell disease. *Curr Gene Ther*. 2015;15(1):64–81.
72. Negre O, Eggimann AV, Beuzard Y, et al. Gene therapy of the β -Hemoglobinopathies by lentiviral transfer of the β (A(T87Q))-Globin gene. *Hum Gene Ther*. 2016;27(2):148–165.
73. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. *Science*. 2007;318(5858):1920–1923.
74. Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. *Blood*. 2012;120(8):1545–1551.
75. Ylä-Herttua S. Glybera's second act: the curtain rises on the high cost of therapy. *Mol Ther*. 2015;23(2):217–218.
76. World Health Organization. *Global Epidemiology of Haemoglobin Disorders and Derived Service Indicators*. World Health Organization; 2008. Available from: <http://www.who.int/bulletin/volumes/86/6/06-036673-ab/en/>.
77. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. *Blood*. 2004;103(6):2039–2045.
78. Sankaran VG, Xu J, Ragozy T, et al. Developmental and species-divergent globin switching are driven by BCL11A. *Nature*. 2009;460(7259):1093–1097.
79. Xu J, Peng C, Sankaran VG, et al. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. *Science*. 2011;334(6058):993–996.
80. Shi L, Cui S, Engel JD, Tanabe O. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. *Nat Med*. 2013;19(3):291–294.
81. Xu J, Bauer DE, Kerenyi MA, et al. Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. *Proc Natl Acad Sci U S A*. 2013;110(16):6518–6523.
82. Amaya M, Desai M, Gnanaprasadam MN, et al. Mi2 β -mediated silencing of the fetal γ -globin gene in adult erythroid cells. *Blood*. 2013;121(17):3493–3501.
83. Peterson KR, Costa FC, Fedosyuk H, et al. A cell-based high-throughput screen for novel chemical inducers of fetal hemoglobin for treatment of hemoglobinopathies. *PLoS One*. 2014;9(9):e107006.
84. Boosalis MS, Castaneda SA, Trudel M, et al. Novel therapeutic candidates, identified by molecular modeling, induce γ -globin gene expression in vivo. *Blood Cells Mol Dis*. 2011;47(2):107–116.
85. Boosalis MS, Sangerman JI, White GL, et al. Novel inducers of fetal globin identified through High Throughput Screening (HTS) are active in vivo in anemic baboons and transgenic mice. *PLoS One*. 2015;10(12):e0144660.
86. Rivers A, Vaitkus K, Ruiz MA, et al. RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases γ -globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model. *Exp Hematol*. 2015;43(7):546–553.
87. Trudel M, De Paepe ME, Chrétien N, et al. Sickle cell disease of transgenic SAD mice. *Blood*. 1994;84(9):3189–3197.

Journal of Blood Medicine

Publish your work in this journal

The Journal of Blood Medicine is an international, peer-reviewed, open access, online journal publishing laboratory, experimental and clinical aspects of all aspect pertaining to blood based medicine including but not limited to: Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases, and Blood banking logistics; Immunohematology; Artificial and alternative

blood based therapeutics; Hematology; Biotechnology/nanotechnology of blood related medicine; Legal aspects of blood medicine; Historical perspectives. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/journal-of-blood-medicine-journal>

Dovepress